Q4 25 EPS
$-1.37
MISS 11.67%
Est. $-1.23
Q4 25 Revenue
$864,000
MISS 78.51%
Est. $4.0M
vs S&P Since Q4 25
+5.3%
BEATING MARKET
CRSP +12.2% vs S&P +6.9%
Full Year 2025 Results
FY 25 EPS
$-6.47
MISS 4.91%
Est. $-6.17
FY 25 Revenue
$3.5M
MISS 42.66%
Est. $6.1M
Market Reaction
Did CRSP Beat Earnings? Q4 2025 Results
CRISPR Therapeutics delivered a sharply disappointing fourth quarter, missing on both top and bottom lines as revenue collapsed and losses widened well beyond expectations. The company posted an EPS loss of $1.37, falling short of the $1.17 consensus… Read more CRISPR Therapeutics delivered a sharply disappointing fourth quarter, missing on both top and bottom lines as revenue collapsed and losses widened well beyond expectations. The company posted an EPS loss of $1.37, falling short of the $1.17 consensus estimate by 17.09%, while revenue came in at just $864,000 against a $3.48 million forecast, a 75.14% miss and a staggering 97.5% decline from the year-ago period. The primary culprit was the absence of CASGEVY collaboration revenue, which had contributed $35.00 million in Q4 2024, combined with a surge in collaboration expenses to $53.70 million from $10.42 million, reflecting the lapse of a cost deferral mechanism under the Vertex agreement. The quarter's weak headline numbers masked genuine commercial progress, however; CASGEVY generated $116.00 million in full-year revenue with patient initiations nearly tripling year-over-year. Looking ahead, pediatric regulatory submissions for ages 5 to 11 are expected in H1 2026, and analysts remain divided on whether pipeline momentum can ultimately justify the company's sustained and deepening losses.
Key Takeaways
- • CASGEVY generated $54 million in Q4 and $116 million for full year 2025 with continued growth in treated patients
- • Patient initiations and first cell collections increased nearly three-fold in 2025 compared to 2024
- • 64 patients received CASGEVY infusions during 2025 including 30 in Q4
- • Approximately 90% of U.S. patients have reimbursed access to CASGEVY
- • Cash position strengthened to $1,975.8 million from $1,903.8 million year-over-year
CRSP YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
CRSP Revenue by Segment
With YoY comparisons, source: SEC Filings
“As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline. We made meaningful advances across multiple clinical and preclinical programs, including encouraging data from zugo-cel in autoimmune disease and oncology, continued global uptake of CASGEVY, and important developments across our in vivo liver editing portfolio, and momentum in our siRNA collaboration with Sirius Therapeutics. At the same time, we continue to strengthen our platform capabilities to support long-term value creation. Together, these developments reflect continued execution across the portfolio.”
— Samarth Kulkarni, Q4 2025 Earnings Press Release
CRSP Earnings Trends
CRSP vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRSP EPS Trend
Earnings per share: estimate vs actual
CRSP Revenue Trend
Quarterly revenue: estimate vs actual
CRSP Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.23 | $-1.28 | -3.68% | $1.5M | -65.73% |
| Q4 25 MISS FY | $-1.23 | $-1.37 | -11.67% | $864,000 | -78.51% |
| FY Full Year | $-6.17 | $-6.47 | -4.91% | $3.5M | -42.66% |
| Q3 25 BEAT | $-1.29 | $-1.17 | +9.23% | $889,000 | -90.07% |
| Q2 25 MISS | $-1.40 | $-2.40 | -71.55% | $892,000 | -86.15% |
| Q1 25 MISS | $-1.28 | $-1.58 | -23.75% | $865,000 | -85.50% |